射頻消融已用於治療肝臟、肺部、腎臟及腎上腺的實體腫瘤。近期，EUS引導RFA已可供使用，該裝置允許以EUS引導治療腹部實體腫瘤。此程序已在豬胰臟中顯示可行，並曾用於治療小群不適合手術的胰臟癌患者。 本研究的目的在於進行一項
適應症：Digestive System Neoplasms
收案條件
納入條件
- Age 18 years-old or above
- Suffering from solid neoplasms of the stomach, liver, kidney or adrenals (\<5cm in largest diameter) that is indicated for treatment.
- Unsuitable for surgery, due to one (or more) of the following items:
- ASA score \> II\*
- An alternative advanced malignancy
- Unsuitable for surgery upon expert's opinion for any other reason
- Healthy individuals who are not keen for surgical resection
- Eligible for endoscopic intervention
- Written informed consent
排除條件
- Coagulopathy (international normalized ratio \>1.3, partial thromboplastin time greater than twice that of control), platelet count \<50,000x103/uL
- Pregnancy
- Patients with a poor mental condition or mental retardation, unable to understand the nature and possible consequences of the study
- Patients unwilling to undergo follow-up assessments
- Patients with liver cirrhosis, portal hypertension and/or gastric varices.
收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。